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1. Introduction  
Anaemia is a common complication of chronic kidney disease (CKD).  The underlying 
physiology related to anaemia in CKD is secondary to reduction in endogenous erythropoietin 
as the glomerular filtration rate (GFR) declines. The introduction of erythropoiesis stimulating 
agents (ESA) has revolutionized the management of anaemia in CKD, leading to substantial 
reductions in the blood transfusion requirements, improvement in energy and physical 
function and small improvements in health-related quality of life (Clement et. al., 2009; 
Eschbach et. al., 1987; Gandra et. al., 2010). Targeting higher haemoglobin with ESA therapy 
has been associated with increased risks of stroke, vascular access thrombosis, hypertension 
and possibly death (Badve et. al., 2011; Besarab et. al., 1998; Palmer et. al., 2010; Pfeffer et. al., 
2009; Phrommintikul et. al., 2007; Singh et. al., 2006). The current KDOQI Clinical Practice 
Guideline recommends a haemoglobin target of 11-12g/dL. However, a substantial proportion 
of non-dialysis and dialysis CKD patients exhibit fluctuations in the haemoglobin levels, also 
known as haemoglobin variability. There is an emerging body of evidence demonstrating an 
association between haemoglobin variability and mortality in CKD patients treated with ESAs. 
Maintaining haemoglobin levels within  narrow target range remains a major challenge in 
clinical practice. The aim of this chapter is to review the definition, prevalence, risk factors of 
haemoglobin variability, and its impact on survival, provide recommendations where possible 
and suggest directions for future research.  
2. Haemoglobin variability 
2.1 Definition 
The definition of haemoglobin variability is not entirely clear and various studies have used 
different definitions. Intra-individual haemoglobin variability is defined as the fluctuation of 
haemoglobin above or below (Kalantar-Zadeh & Aronoff 2009) or even within the target 
range over time. Methods to quantify haemoglobin variability are summarised below. 
1. Standard deviation of the differences between observed haemoglobin values and 
haemoglobin slope which represents the mean haemoglobin change over time (Yang et. 
al., 2007).  
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2. Intra-individual standard deviation of 3-month haemoglobin rolling average (Lacson et. 
al., 2003). 
3. Using 3 haemoglobin groups (above/below/within the target) for each of the 6 
consecutive monthly haemoglobin values, classification of all patients into 6 groups: (i) 
consistently low, (ii) consistently high, (iii) consistently within the target range, (iv) low 
amplitude fluctuation with low haemoglobin values (all-6 mo with low or target-range 
haemoglobin values), (v) low amplitude fluctuation with high haemoglobin values (all-
6 mo with high or target-range haemoglobin values), and (vi) high amplitude 
fluctuation with high haemoglobin values (low, high and target-range haemoglobin 
values within 6-mo period) (Ebben et. al., 2006). 
4. Time-in-target haemoglobin range (De Nicola et. al., 2007). 
5. Determining velocity (or deflection) of haemoglobin change by averaging slopes 
between successive haemoglobin values (Lau et. al., 2010).  
6. Change in haemoglobin in 6-mo above and below the reference range (based on the 
median change in haemoglobin in 6-mo) (Regidor et. al., 2006). 
2.2 Prevalence 
Haemoglobin variability is common not only in patients with end-stage kidney disease 
(ESKD) on dialysis, but also in CKD patients who are not yet on dialysis (non-dialysis CKD). 
The reported prevalence of haemoglobin variability in non-dialysis CKD patients varies 
between 61 to 86% (Boudville et. al., 2009; Minutolo et. al., 2009). On the other hand, 82 to 
90% of ESKD patients on dialysis exhibit haemoglobin variability (Ebben et al., 2006; 
Eckardt et. al., 2010; Gilbertson et. al., 2009). 
3. Risk factors  
3.1 ESA therapy  
Requirement of ESA for the treatment of anaemia in CKD is a major risk factor for 
haemoglobin variability. In a study involving 6,165 non-dialysis CKD patients, only 47% of 
patients who were not treated with any ESAs demonstrated fluctuations in haemoglobin 
(Boudville et al., 2009). However, 73% of patients who were already treated with ESAs 
experienced haemoglobin variability. This prevalence further increased to 77% among 
individuals who were commenced on ESAs as a new therapy. Patients treated with ESA 
therapy for a longer duration were less likely to have haemoglobin variability. Each 3-mo 
increment in the duration of ESA therapy decreased the risk of haemoglobin variability by 
6%. In a study involving 5,037 ESKD patients on haemodialysis, the risk of developing 
haemoglobin variability was more than twice in patients on ESAs, compared to those not on 
ESAs (Eckardt et al., 2010). These findings suggest that the need of ESA rather than ESA 
therapy per se leads to haemoglobin variability (See Table 1). 
There is increased interest in studying the effect of various anaemia management protocols 
on haemoglobin variability. Patel and colleagues studied the effect of route of 
administration of erythropoietin on haemoglobin variability in a post hoc analysis of a 
randomised controlled trial involving 157 prevalent ESKD patients on dialysis (Patel et. al., 
2009). Over a follow up of 24-weeks, compared to patients treated with intravenous 
erythropoietin, those treated with subcutaneous erythropoietin were more likely to have (i)  
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Factors related to ESA therapy 
Route of administration 
Long versus short acting ESA 
Responsiveness to the first dose of ESA 
Haemoglobin before initiation of ESA 
Iron supplementation 
Frequency of the ESA dose adjustments 
Magnitude of the ESA dose adjustments 
Patient-level factors 
Age 
Gender 
Body mass index 
Incident versus prevalent dialysis 
Comorbid conditions 
Number and duration of hospitalisation 
Use of catheter as haemodialysis vascular access 
Facility-level anaemia management protocols 
Proportion of patients prescribed ESAs 
Frequency of haemoglobin monitoring  
Frequency of ESA dose monitoring 
Wider range of target haemoglobin 
Higher upper target range of haemoglobin 
Table 1. List of possible factors affecting haemoglobin variability 
haemoglobin concentrations outside the target range for more weeks (13.9 ± 4.7 weeks 
versus 12.5 ± 5 weeks, p=0.04) and (ii) higher standard deviation of haemoglobin (0.84 ± 0.35 
versus 0.74 ± 0.27, p=0.01). Interestingly, in one report, the risk of developing haemoglobin 
variability was greater with long-acting ESAs (Boudville et al., 2009). De Nicola and 
colleagues did not find any association between long-acting ESAs versus erythropoietin and 
haemoglobin variability (De Nicola et al., 2007). However, they observed that baseline 
haemoglobin level, first dose of ESA and initial iron supplementation were directly 
associated with the length of time-in-target haemoglobin. 
Depending on the 6-group classification based on the highest and lowest categories of 
haemoglobin, Gilbertson and colleagues reported that patients in the low-intermediate group 
received high doses of erythropoietin and more blood transfusions (Gilbertson et al., 2009). 
Minutolo and colleagues found that haemoglobin variability was associated with 
responsiveness to the first dose of erythropoietin (Minutolo et al., 2009). They also observed 
that a change of erythropoietin dosage occurred less frequently than expected in spite of 
regular follow up visits. Therefore, they concluded that lack of adjustment of erythropoietin 
dosage can lead to haemoglobin variability. However, their data on the effect of frequency and 
magnitude of adjustment of erythropoietin dosage on haemoglobin stabilisation is less clear. In 
a post hoc analysis of a randomised controlled trial involving 154 ESKD patients on 
haemodialysis, more frequent adjustments of erythropoietin dosage as well as larger changes 
of erythropoietin dosage were associated with haemoglobin variability (Lau et al., 2010). 
Using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) involving 
26,510 patients, Pisoni and colleagues studied the associations between facility-level 
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anaemia management practices and facility-level haemoglobin standard deviations (Pisoni 
et. al., 2011). This study identified factors that decreased haemoglobin variability which 
include reviewing ESA dose at least twice a week and checking haemoglobin levels on a 
weekly basis. There was also less haemoglobin variability in facilities with a greater 
percentage of patients prescribed an ESA likely related to better anaemia management with 
the introduction of an ESA and fewer patients outside the target haemoglobin concentration. 
The factors that were more likely associated with haemoglobin variability were: facilities 
with a wider target haemoglobin range, higher upper target haemoglobin, and ESA 
administration by subcutaneous route (compared to intravenous route).  
3.2 Patient-level factors 
Various studies have reported that young age is a risk factor for haemoglobin variability (De 
Nicola et al., 2007; Eckardt et al., 2010). Boudville and colleagues reported that the odds of 
haemoglobin variability decreased by 11% with each 10-yr increment in age (Boudville et al., 
2009). A few studies have reported that women were more likely to have fluctuations in the 
haemoglobin concentration (Ebben et al., 2006; Gilbertson et. al., 2008). In a study of 119 
non-dialysis CKD patients, male gender was directly associated with increased time-in-
target haemoglobin (De Nicola et al., 2007).  
Eckardt and colleagues studied the magnitude and frequency of haemoglobin variability as 
a quantitative index by integrating the area under the curve (AUC) between measured 
haemoglobin values and the mean haemoglobin concentration (Eckardt et al., 2010). High 
degree of haemoglobin variability was defined as AUC >50th percentile. The mean body 
mass index (BMI) was lowest in the highest quartile of AUC. On multivariate logistic 
regression, BMI 25 to 30 kg/m2 and >30 kg/m2 were independently associated with 
decreased odds of haemoglobin variability compared to the reference category of BMI 18 to 
25 kg/m2. Similarly, Lau and colleagues also observed less positive deflection of 
haemoglobin in heavier patients (Lau et al., 2010). 
There is an excess burden of comorbid conditions in CKD, leading to erythropoietin 
hyporesponsiveness. In an observational study involving 152,846 ESKD patients on 
haemodialysis, Ebben and colleagues reported that having 2 or more comorbid conditions, 6 
or more days of hospitalisation, and occurrence of infectious hospitalisations were 
independently associated with haemoglobin variability (Ebben et al., 2006).  
Eckardt and colleagues found that incident dialysis vintage, change in haemodialysis 
vascular access, use of catheter for haemodialysis, haemoglobin lower than 11 g/dL, use of 
angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and 
hospitalisation were positively associated with an increased risk of haemoglobin variability 
(Eckardt et al., 2010). Also, patients treated with an ESA were twice likely to experience 
hemoglobin variability than those not treated with an ESA. As expected, higher serum 
albumin concentration was negatively associated with haemoglobin variability. 
Interestingly, history of cardiovascular disease was negatively associated with haemoglobin 
variability. Furthermore, the investigators did not find any association of C-reactive protein 
and leukocyte count with haemoglobin variability. The reasons for these findings are not 
entirely clear, but this study included a highly selected cohort in whom complete data on 
monthly haemoglobin values for 6 mo and medications were available, raising a possibility 
of selection bias. Similarly, Lau and colleagues also found a positive association between 
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catheter use and haemoglobin variability; and a negative association with high baseline 
haemoglobin (Lau et al., 2010).  
Weinhandl and colleagues studied the risk factors for haemoglobin variability in Medicare 
haemodialysis patients (Weinhandl et. al., 2011). The study cohort included 3 groups of 
haemodialysis patients: historical prevalent (prevalent on July 1, 1996; n=78,602), 
contemporary prevalent (prevalent on July 1, 2006; n= 133,246), and incident (January 1, 
2005 - June 30, 2006; n=24,999). In both the prevalent groups, the presence of all comorbid 
conditions, except hepatic disease, was associated with greater haemoglobin variability. 
These conditions included atherosclerotic heart disease, congestive heart failure, arrhythmia 
and other cardiac diseases, cerebrovascular disease, peripheral vascular disease, cancer, 
chronic obstructive pulmonary disease, diabetes and gastrointestinal bleeding. In the 
incident group, the presence of cerebrovascular disease, peripheral vascular disease, chronic 
obstructive pulmonary disease, diabetes and gastrointestinal bleeding were associated with 
haemoglobin variability. In all 3 groups, cumulative hospital days and number of months 
with haemoglobin <10 g/dL were positively associated with haemoglobin variability. 
Similar findings have been reported by Gilbertson and colleagues (Gilbertson et al., 2009). 
3.3 Facility-level factors 
Pisoni and colleagues studied facility-level risk factors for haemoglobin variability in 26,510 
haemoglobin patients from 930 facilities in 12 countries using the DOPPS data (Pisoni et al., 
2011). Haemoglobin variability was not associated with the number of haemodialysis 
patients per facility. However, larger differences in mean facility-level haemoglobin 
standard deviation were seen between countries. The mean age was nearly 2 years younger 
in the highest quartile of facility-level haemoglobin standard deviation than the lowest 
quartile. The investigators found that BMI, neutrophil count, and prevalence of psychiatric 
disorders and hepatitis C were higher in facilities with higher facility-level haemoglobin 
standard deviation. They also observed a positive association between haemoglobin 
variability and increased proportion of patients in a facility with parathyroid hormone level 
>450 pg/mL. Furthermore, the investigators reported a strong correlation (r =0.56) between 
facility-level haemoglobin standard deviation and within-patient haemoglobin standard 
deviation. These findings suggest that the results of this facility-level study could be 
generalised to an individual patient.  
4. Association between haemoglobin variability and mortality 
An emerging body of evidence suggests that haemoglobin variability is associated with 
increased risk of all-cause death in both non-dialysis CKD and ESKD patients. Boudville 
and colleagues found an association between haemoglobin variability and death not only in 
non-dialysis CKD patients treated with ESAs (n=1,823), but also in those who were not on 
ESAs (n=3,143) (Boudville et al., 2009). For each 1 g/L increase in the residual standard 
deviation, HR (95%CI) for patients on ESA throughout the study and those who were not 
receiving ESA were 1.02 (1.01 to 1.04) and 1.03 (1.02 to 1.05), respectively. The analysis of the 
pooled data from these 2 groups showed similar results. Compared to patients with 
haemoglobin levels consistently within the target range, those with low amplitude 
fluctuation with low haemoglobin values (HR 1.62, 95%CI 1.36 to 1.94) and high amplitude 
fluctuation (HR 1.57, 95%CI 1.24 to 1.98) were at increased risk of all-cause mortality. 
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Minutolo and colleagues reported that longer time with haemoglobin within the target range 
of 11 to 13 g/dL was associated with decreased risk of renal death (defined as a composite 
endpoint of all-cause death on dialysis or after kidney transplantation) (Minutolo et al., 2009).  
In a study involving 34,963 haemodialysis patients who were enrolled in the Fresenius 
Medical Care database in 1996, Yang and colleagues reported that the risk of all-cause 
mortality increased proportionately with haemoglobin variability (Yang et al., 2007). The 
hazard ratio and 95% confidence intervals (CI) per 0.50 g/dL, 0.75 g/dL, 1.00 g/dL, and 1.50 
g/dL increases in haemoglobin variability were 1.15 (1.10 to 1.20), 1.24 (1.16 to 1.32), 1.33 
(1.22 to 1.45), and 1.53 (1.35 to 1.75), respectively.  
Gilbertson and colleagues found that out of 6 categories of haemoglobin variability 
(categorized as low <11g/dL, intermediate 11 – 12.5g/dL & high >12.5g/dL and further 
divided into low-low, intermediate-intermediate, high-high, low-intermediate, 
intermediate-high, low-high), patients in the low-high and low-intermediate groups 
experienced an increased risk of death compared with those in the intermediate-
intermediate group (Gilbertson et al., 2008). The HR and 95%CI for the low-high and low-
intermediate groups were 1.19 (1.10 to 1.28) and 1.44 (1.33 to 1.56), respectively. Although 
this categorization broadly identifies patients with stable hemoglobin and either low or high 
amplitude fluctuations in hemoglobin, it assumes a unidirectional and linear change in 
hemoglobin. 
Lau and colleagues measured haemoglobin variability as rate of haemoglobin change: 
average positive-only (positive haemoglobin deflections) and average negative-only 
(negative haemoglobin deflections) (Lau et al., 2010). While negative haemoglobin 
deflections were not associated with mortality risk (HR 1.07, 95% CI 0.94 to 1.21 per 
g/L/week), rapid rise in haemoglobin was associated increased risk (HR 1.23, 95% CI 1.03 
to 1.48 per g/L/week). 
Regidor and colleagues analysed a cohort of 58,058 prevalent haemodialysis patients from 
the DaVita dialysis organisation (Regidor et al., 2006). Compared to patients whose 
haemoglobin remain unchanged during the first 6 mo of the 2-year cohort study period, the 
risks of all-cause and cardiovascular mortality were significantly higher in patients with 
reduction in haemoglobin by more than 1.50 g/dL/quarter. In the fully-adjusted model 
(adjusted for demographic characteristics, comorbidities, smoking, dialysis dose, nutritional 
status, iron studies, doses of ESAs and iron), there was no association observed with 
increment in haemoglobin and mortality. However, decrease in hemoglobin was associated 
with increased mortality. While this study described an association between change in 
hemoglobin per quarter and mortality, it did not specifically study an association between 
hemoglobin variability and mortality. 
Pisoni and colleagues reported mortality outcomes using haemoglobin variability at the 
facility-level using the DOPPS database (Pisoni et al., 2011). In the adjusted model, the HR 
for every 0.5 g/dL higher facility-level haemoglobin standard deviation was 1.08 (95% CI 
1.02 to 1.15). Compared to the reference category of the lowest quartile of facility-level 
haemoglobin standard deviation, the HR (95% CI) for the 2nd, 3rd and 4th quartiles were 1.08 
(1.10 to 1.34), 1.15 (1.35 to 1.69) and 1.19 (1.04 to 1.37), respectively. As previously 
mentioned, the facility-level haemoglobin standard deviation correlated well with within-
patient haemoglobin standard deviation. 
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Not all studies have demonstrated a positive association between haemoglobin variability 
and death in CKD. Eckardt and colleagues studied the effect of haemoglobin variability on 
mortality using 5 definitions: within-patient standard deviation, residual standard 
deviation, time-in-target haemoglobin, amplitudes of fluctuation, and AUC (Eckardt et al., 
2010). In the adjusted Cox regression model, haemoglobin variability was not a statistically 
significant factor in all 5 methods, except for the group of patients with low amplitude 
fluctuations with low haemoglobin levels (HR 1.74, 95%CI 1.00 to 3.04). However, 95% 
confidence intervals were very wide and the lower 95% confidence interval was 1.00. Thus, 
although this association was statistically significant, it was weak. 
Brunelli and colleagues included a retrospective cohort of 6,644 incident patients who 
commenced haemodialysis between 2004 and 2005 from the Fresenius Medical Centre 
database (Brunelli et. al., 2008). In contrast to their 1996 cohort study results (Yang et al., 
2007), the association between haemoglobin variability and mortality was not statistically 
significant. The unadjusted and adjusted HR (95%CI) for were 0.96 (0.81 to 1.14) and 1.11 
(0.92 to 1.33), respectively. The discrepancy in these analyses may be explained by the 
addition of a large number of variables in the Cox regression model for the 2004-2005 cohort 
as more data were available. Consequently, when the analysis was restricted using the same 
limited variables as in the 1996 cohort study; the association achieved statistical significance 
with a HR of 1.22 (1.01 to 1.48).  Although the investigators have attempted to adjust for 
known variables, the possibility of residual confounding could not be excluded. The 
complexity of these statistical models makes interpretation of the results difficult, 
particularly when the different statistical methods or approaches did not generate robust or 
consistent findings.  
Weinhandl and colleagues reported the association between haemoglobin variability and 
all-cause mortality using 3 Cox proportional hazards regression models (Weinhandl et al., 
2011). In the case-mix-adjusted model, the HR (95%CI) for the contemporary prevalent, 
historical prevalent and incident groups for 1 g/dL haemoglobin variability were 1.27 (1.24 
to 1.31), 1.32 (1.27 to 1.38) and 1.08 (1.03 to 1.13), respectively. In the comorbid condition-
adjusted model, haemoglobin variability was associated with increased risk of death in both 
the prevalent groups with a HR of 1.07 (1.04 to 1.10) in the contemporary prevalent group 
and 1.10 (1.06 to 1.15) in the historical prevalent group. However, there was no statistically 
significant association in the incident group (HR 1.03, 95%CI 0.98 to 1.09). In the expanded 
comorbid condition-adjusted model, the statistically significant association was limited only 
to the historical prevalent group (HR 1.07, 95%CI 1.03 to 1.12). Haemoglobin variability was 
not associated with increased risk of death in either the contemporary prevalent (HR 1.02, 
95%CI 0.99 to 1.05) or incident groups (HR 1.01, 95%CI 0.95 to 1.06). These findings suggest 
that the association between haemoglobin variability and mortality was weak in this study 
and was sensitive to adjustment for concurrent disease severity.  
5. Management of haemoglobin variability  
Since the introduction of ESAs, most of the clinical trials with ESA therapy have focused on 
haemoglobin targets in CKD patients. There is a shortage of clinical trials studying the 
optimal strategy for haemoglobin monitoring in patients treated with ESAs and 
interventions to reduce haemoglobin variability.  
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Ho and colleagues conducted an observational case-control study of unselected ESKD 
patients on haemodialysis (Ho et. al., 2010). Patients served as their own control. They 
compared 2x/month laboratory haemoglobin measurements and use of a computerised 
algorithm to analyse 12x/month monitoring of Crit-line haemoglobin measurements. They 
found that haemoglobin variability, measured by the mean standard deviation of the 
residuals, significantly improved during the phase of frequent haemoglobin monitoring. 
However, this was not a randomised controlled trial. Also, the sample size was small and it 
was an unblinded study in a single-centre. Nonetheless, the study highlights the importance 
of frequent monitoring of haemoglobin as it may provide an opportunity to titrate the ESA 
dose early.  
Gaweda and colleagues conducted a case-controlled observational study in which 49 ESKD 
patients on haemodialysis were included (Gaweda et. al., 2010). The investigators measured 
haemoglobin using Crit-line at various intervals: twice weekly or 8x/mo, once weekly or 
4x/mo, every 2 weeks or 2x/mo and every 4 weeks or 1x/mo.  They also calculated the 
haemoglobin estimation error as a root mean-squared difference between the observed and 
estimated haemoglobin and compared it with the measurement error. They found that the 
most accurate haemoglobin estimation was achieved with twice weekly haemoglobin 
sampling, although it exceeded the accuracy of the measurement device. Twice and once 
weekly haemoglobin measurements were found to be optimal in 31% and 45% patients, 
respectively. This was also a single-centre study with a small sample size. 
These two studies highlight the paucity of evidence in the area of management of 
haemoglobin variability. Considering the cost and possible amount of blood loss associated 
with frequent hemoglobin monitoring, currently available evidence is not sufficient to make 
any clinical practice recommendations.   
6. Future research  
There is substantial heterogeneity in the haematological response to ESAs. Although the 
factors underpinning ESA-hyporesponsiveness are well characterised, those contributing to 
haemoglobin variability are poorly understood. Future studies should include prospective 
and systematic data collection to evaluate these factors. Investigations should also be carried 
out to develop a single and uniformly accepted method to measure haemoglobin variability 
that is clinically relevant and reproducible, since there is no consensus on a single method 
for the measurement of haemoglobin variability.  
The data on the effect of haemoglobin variability on mortality are conflicting. This could be 
due to several reasons. Firstly, most of the data originates from retrospective and 
observational studies. Secondly, the studies are arbitrarily limited to sampling during 6 
month periods where monthly haemoglobin values for each month were available. This 
cross-sectional nature of the study does not reflect long-term fluctuations in haemoglobin 
values. Thirdly, due to highly selective nature of the study cohorts, sampling bias could be 
potentially introduced. Most of these studies had a very short follow up period ranging 
from 6 months to 18 months. Furthermore, different statistical models have demonstrated 
inconsistent and non-reproducible results due considerable between-study variation in the 
covariates included in the adjusted models. Therefore, the exact nature and quantification of 
the effect of haemoglobin variability on mortality is still poorly understood.  
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Future studies should be designed carefully and conducted prospectively to define the exact 
magnitude of the effect of haemoglobin variability on mortality. They should also include a 
greater breadth and depth of the CKD patient populations since dialysis studies have not 
included patients receiving peritoneal dialysis and studies involving non-dialysis CKD 
patients have been very limited. 
Most of the current data is merely hypothesis generating. Therefore, well designed and 
adequately powered randomised controlled trials are needed to determine the optimal 
frequency of haemoglobin monitoring along with a cost-effective analysis. Further trials are 
required to define the optimal strategy of frequency and magnitude of ESA and iron dose 
changes, and study their possible interactions with concurrent acute illness and the presence 
of comorbid conditions. 
7. Summary 
Haemoglobin variability is highly prevalent in both non-dialysis and dialysis CKD patients. 
The factors contributing to haemoglobin variability are not entirely clear. However, the 
currently available evidence has identified the following factors: younger age, female 
gender, low body mass index, the presence of comorbid conditions, and the use of ESA and 
less frequent monitoring of haemoglobin. There is conflicting evidence on the effect of 
haemoglobin variability on mortality with some studies demonstrating a strong association 
and others showing no association with mortality. A few small prospective observational 
studies have found that frequent monitoring of haemoglobin may reduce short-term 
haemoglobin variability, although the optimal frequency of haemoglobin monitoring is yet 
to be defined. Evidence-based treatment strategies cannot be currently recommended due to 
a lack of high quality data. In conclusion, maintaining haemoglobin within a target range 
continues to pose a challenge to clinicians. Further research is urgently needed in this 
insufficiently researched field.  
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